 Home > Active Ingredient News > Immunology News > European Commission approves TREMFYA ® (guselkumab) for the treatment of active psoriasis arthritis (PsA)

European Commission approves TREMFYA ® (guselkumab) for the treatment of active psoriasis arthritis (PsA)

 Last Update: 2020-12-14
 Source: Internet
 Author: User

Tags

human adipose tissue

rheumatoid factor 14

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Johnson and Johnson Pharmaceuticals announced today that the European Commission (EC) has approved TREMFYA® (guselkumab) for the treatment of adult patients with active psoriasis arthritis (PsA), who are not responsive or insufficiable to previous treatments for anti-disease rheumatoid drugs (DMARD).
Guselkumab is the first approved all-human monoclonal antibody that selectively binds to the p19 sub-base of erythrogen (IL)-23 and inhibits its interaction with the IL-23 receptor.
has been approved for the treatment of patients with moderate to severe psoriasis.
IL-23 is an important driver of the progression of inflammatory diseases, including psoriasis and PSA.
PsA is a chronic immune-mediated inflammatory disease characterized by joint damage and inflammation in addition to enteritis, mastitis, axon disease and skin lesions associated with psoriasis.
, stiffness and swelling of the joints and connective tissue can be severe and make daily work difficult.
there is no cure for PSA, and it is estimated that one-third of Europe's 14 million psoriasis patients will continue to develop PSA.
。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.